Abstract
Background Large language models (LLMs) such as GPT-4 hold great promise as transformative tools in healthcare, ranging from automating administrative tasks to augmenting clinical decision- making. However, these models also pose a serious danger of perpetuating biases and delivering incorrect medical diagnoses, which can have a direct, harmful impact on medical care.
Methods Using the Azure OpenAI API, we tested whether GPT-4 encodes racial and gender biases and examined the impact of such biases on four potential applications of LLMs in the clinical domain—namely, medical education, diagnostic reasoning, plan generation, and patient assessment. We conducted experiments with prompts designed to resemble typical use of GPT-4 within clinical and medical education applications. We used clinical vignettes from NEJM Healer and from published research on implicit bias in healthcare. GPT-4 estimates of the demographic distribution of medical conditions were compared to true U.S. prevalence estimates. Differential diagnosis and treatment planning were evaluated across demographic groups using standard statistical tests for significance between groups.
Findings We find that GPT-4 does not appropriately model the demographic diversity of medical conditions, consistently producing clinical vignettes that stereotype demographic presentations. The differential diagnoses created by GPT-4 for standardized clinical vignettes were more likely to include diagnoses that stereotype certain races, ethnicities, and gender identities. Assessment and plans created by the model showed significant association between demographic attributes and recommendations for more expensive procedures as well as differences in patient perception.
Interpretation Our findings highlight the urgent need for comprehensive and transparent bias assessments of LLM tools like GPT-4 for every intended use case before they are integrated into clinical care. We discuss the potential sources of these biases and potential mitigation strategies prior to clinical implementation.
Competing Interest Statement
T.Z. reports no external financial interests. He works in an unpaid role as a clinical consultant with Xyla Inc. E.L. reports a role as a machine learning scientist with Xyla Inc. M.S. reports personal fees from Xyla and serves as an intern at Microsoft Research. A.J.B. is a co-founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook), Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi, Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences, Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. A.J.B. receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. A.J.B.'s research has been funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governor's Office of Planning and Research, California Institute for Regenerative Medicine, L'Oreal, and Progenity. E.A. reports personal fees from Canopy Innovations, Fourier Health, and Xyla Inc. and grants from Microsoft Research. None of these entities had any role in the design, execution, evaluation, or writing of this manuscript.
Funding Statement
T.Z. is funded by a T32 NCI Hematology/Oncology training fellowship grant. M.S. and D.J. gratefully acknowledge the support of Open Philanthropy and the NSF (via Award IIS-2128145). Partial funding for this work is from a philanthropic gift from Priscilla Chan and Mark Zuckerberg.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵∗ Equal contribution
Fix author email in metadata.
Data Availability
All data produced in the present work are contained in the manuscript or on the Github.
